A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, ...

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on Intra-Cellular Therapies (ITCI – Research Report), ...

Major deals, including Johnson & Johnson’s $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

Fintel reports that on January 31, 2025, Canaccord Genuity downgraded their outlook for Intra-Cellular Therapies ...

In a report released on January 27, Jessica Fye from J.P. Morgan maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), ...

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus away from enormous takeovers to single-digit billion buy outs.

Fintel reports that on January 22, 2025, RBC Capital downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) from Outperform to Sector Perform. Analyst Price Forecast Suggests 17.02% ...

In the preceding three months, 6 analysts have released ratings for Intra-Cellular Therapies ITCI, presenting a wide array of perspectives from bullish to bearish. The table below provides a ...